Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

MuGard Provides Significant Improvement or Stabilization of Oral Mucositis in Over 75% of Patients in European Clinical Experience

October 11, 2010 By Bio-Medicine.Org

DALLAS and NEW YORK, Oct. 11 /PRNewswire-FirstCall/ — Access Pharmaceuticals,
Inc.
(OTC Bulletin Board:
ACCP), a biopharmaceutical company specializing in products for
cancer and supportive care, announced the highlights from a poster
presentation on European clinical experience of MuGard at this
year’s European Society of Medical Oncology Conference in Milan,
Italy.  Some of the findings reported in the ESMO presentation
included:

MuGard provided a significant improvement and/or stabilization of
oral mucositis lesions and symptoms of oral mucositis (OM) in more
than 75% of cancer patients treated with radiotherapy/chemotherapy;
Patients reported a 52% significant reduction in oral discomfort
(oral pain and swallowing ability) in patients with pre-existing
lesions of OM, and reported a substantial reduction in the use of
pain medication; MuGard has a ready-to-use formulation that is well
accepted by 86% of patients, as reported in this assessment
program; No MuGard-related adverse reactions have been identified
in clinical practice; MuGard represents a valuable therapeutic
option in the treatment and prevention of OM in cancer patients
undergoing radio/chemotherapy.

“These additional findings out of Europe are very exciting and
strengthen our belief in the clinical benefits that MuGard can
provide patients undergoing radiation and chemotherapy,” said
Jeffrey Davis, CEO of Access Pharmaceuticals.  He continued,
“This data confirms the competitive advantages of MuGard over the
current treatment options on the market and we will use this data
to educate patients, clinicians and the medical industry on the
superior attributes of our product.”

Earlier this year, Access presented MuGard data and clinical
experience at the MASCC Conference (Multinational Association of
Supportiv

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech